Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: Outcomes of sentinel node biopsy according to MRI response in an association with the subtypes in cN1–3 breast cancer after neoadjuvant systemic therapy, multicenter cohort study

Fig. 2

The rates of complete MRI response. In the GSH-YCC cohort, 207 patients had HR+ HER2− breast cancer and 181 patients had HER2+ breast cancer (n = 181). Of the 388 patients, 55 (14.2%) were complete MRI responders, 25 (12.1%) of 207 patients in HR+ HER2−, and 30 (16.6%) of 181 patients in HER2+ or TNBC. In the validation cohort (AMC-SMC) consisting of 288 patients with HER2+ or TNBC, 47 (17.7%) patients achieved complete MRI response after NAST. HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us